Stopping Wegovy mid-course: what the science says about pausing GLP-1 therapy

What's this video probably claiming?

Based on the caption and hashtags, the creator appears to be documenting a personal decision to pause or stop their Wegovy (semaglutide 2.4 mg) injections, likely in connection with a breast reduction surgery. The hashtags #breastreduction and #secondbreastreduction alongside #healthanxiety suggest the stop was either surgeon-mandated pre-operatively or driven by anxiety about combining a relatively new medication with surgical recovery. This is a genuinely common scenario that doesn't get nearly enough honest discussion online. Surgeons do sometimes recommend pausing GLP-1 therapy before elective procedures, partly due to concerns about gastroparesis-related aspiration risk under general anesthesia, and partly out of caution around healing and nutritional status. The creator is probably sharing their experience of stopping injections, possibly describing side effects of discontinuation or weight regain fears.

What does the science actually show?

Stopping semaglutide abruptly is not trivial. The STEP 4 trial (Rubino et al., 2021, JAMA) is the clearest data we have here: participants who discontinued semaglutide after 20 weeks of dose escalation regained approximately two-thirds of their lost weight within one year. That's a real and significant effect. On the surgical side, the American Society of Anesthesiologists issued guidance in 2023 recommending patients on weekly GLP-1 agonists consider holding the dose for one week before elective procedures, citing case reports of retained gastric contents even after standard fasting. This is not settled science, it's precautionary guidance based on limited data. A 2023 retrospective study by Silveira et al. in Obesity Surgery found no statistically significant difference in aspiration events between GLP-1 users and non-users undergoing bariatric procedures, though sample sizes were limited. The anxiety piece is real too: health anxiety around medication side effects is documented in GLP-1 users, particularly around injection site reactions and gastrointestinal symptoms at higher doses.

Where does the social media noise diverge from clinical reality?

The biggest distortion in GLP-1 content on TikTok right now is the framing of stopping Wegovy as either catastrophic or no big deal, depending on who's posting. Neither is accurate. Rebound weight gain after discontinuation is well-documented but not universal, and it is not instant. Most regain in the STEP 4 data occurred gradually over 52 weeks, not in the first few days after stopping. Creators also tend to conflate the emotional experience of stopping with medical necessity, which muddies the waters for viewers trying to make their own decisions. The surgical pause recommendation is being applied inconsistently by different surgeons, and there is no standardized protocol yet. Some anesthesiologists are asking for two-week holds, others one week, others nothing at all. Presenting a surgeon's personal caution as universal fact, or dismissing it entirely, are both problems you see regularly in this content category.

What should you actually know?

If you are on Wegovy and facing elective surgery, talk to both your prescribing provider and your anesthesiologist, not just one of them. The ASA's 2023 guidance is precautionary, not a regulatory mandate, and your specific situation matters. Fasting protocols, procedure length, and your individual GI motility history all factor in. On the discontinuation side, the evidence strongly suggests that semaglutide needs to be continued long-term to maintain weight loss outcomes. The STEP 1 extension data and STEP 4 both confirm this. Stopping for a few weeks around surgery is unlikely to cause permanent harm, but if you stop and don't restart, expect gradual weight regain over months. Health anxiety is a legitimate concern worth addressing directly with a provider, not just by stopping medication. If injection anxiety or side effect fear is driving discontinuation, that is a clinical conversation, not just a lifestyle choice.